生命科学资讯

In the clinic for March 2, 2026

Other news to note for March 2, 2026

Regulatory actions for March 2, 2026

Roche pill succeeds in another MS study, but approval questions linger

United Therapeutics to take pulmonary hypertension drug to FDA for approval

Aardvark's stock plummets on study pause; BioNTech heads to Phase 3 with DualityBio ADC

Candid, in a reverse merger with RallyBio, to go public

BioAtla lays off 70% of workforce, searches for buyers for antibody pipeline

United Therapeutics’ phase 3 win tees up filing to challenge J&J in cardiac condition

UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy

FDA fully releases clinical hold on Intellia CRISPR gene therapy trials

Thermo Fisher Scientific Launches New Color-Based (Chromogenic) Culture Media to Help Detect Candida Infections Faster*, Including Drug-Resistant Candida auris - BioSpace

Roche gets third pivotal win with MS drug, but liver signal could be a problem

FDA lifts hold on second Intellia Phase 3 gene editing trial

Stifel raises 10X Genomics stock price target on product adoption - Investing.com

Uniqure falls as FDA demands new trial for Huntington’s gene therapy

Med-tech outlook 2026: exits, financings, headwinds

Biggest gainers and losers for Feb. 23-27, 2026

Stifel raises 10X Genomics stock price target on product adoption - Investing.com

Candid to go public via reverse merger with Rallybio